medcart
Delivery Pincode
Enter Pincode
View Cart
Login | Signup
Padlas-L 40mg/240mg Tablet
Share
medicinePrescription Required.Why?
Marketer
Aden Healthcare
Composition
Artemether (40mg) + Lumefantrine (240mg)
100% Genuine Products
Safe & Secure Payment
Contact Less Delivery
Fully Sanitized Packing
About Padlas-L 40mg/240mg Tablet
Padlas-L 40mg/240mg Tablet (Artemether + Lumefantrine) is a combination medication used to treat uncomplicated malaria caused by Plasmodium falciparum. It works by killing the parasites and preventing their multiplication. It is usually taken with a fatty meal and should be swallowed whole. Common side effects include nausea, vomiting, diarrhea, stomach pain, and headache. You should avoid alcohol consumption during treatment and be cautious while driving. This medication is not recommended for pregnant women and requires a different dosage for children. Seek medical advice if you have any pre-existing medical conditions or experience serious side effects.
Ingredients of Padlas-L 40mg/240mg Tablet

Artemether + lumefantrine is a combination antimalarial medication.

Artemether is an artemisinin derivative that acts quickly to kill malaria parasites.

Lumefantrine is a long-acting antimalarial that prevents the parasites from multiplying.

Direction for Use of Padlas-L 40mg/240mg Tablet

    Treatment of uncomplicated malaria caused by Plasmodium falciparum, the most dangerous type of malaria parasite.

    Suitable for adults and children weighing over 5 kg.

How Padlas-L 40mg/240mg Tablet Works

Padlas-L 40mg/240mg Tablet (Artemether + Lumefantrine) work together to eliminate malaria parasites from the body. Artemether quickly kills the parasites, while lumefantrine prevents them from multiplying. This combination ensures a more effective and sustained treatment of malaria.

Storage and Handling of Padlas-L 40mg/240mg Tablet

Store the medication in a cool, dry place, away from direct sunlight and moisture.

Dosage of Padlas-L 40mg/240mg Tablet

    Dosage varies depending on the patient's weight and age. Always follow the prescribed dosage and duration of treatment.

    The medication is usually taken with a fatty meal for better absorption.

    The tablets should be swallowed whole with water, and should not be chewed or crushed.

Side effects of Padlas-L 40mg/240mg Tablet

    Common side effects include nausea, vomiting, diarrhea, stomach pain, and headache.

    Less common side effects include dizziness, fatigue, skin rash, itching, and muscle aches.

Safety Consideration or Warnings
    Alcohol Consumption

    Avoid alcohol consumption during treatment as it can increase the risk of side effects.

    While Driving or Operating Machinery

    Be cautious while driving or operating machinery as this medication can cause dizziness.

    Pregnant & Breastfeeding Women

    This medication is not recommended for pregnant women, especially in the first trimester. Consult your doctor for advice.

    Children

    Dosage and safety are different for children. Consult your doctor for the appropriate dosage.

    Kidney

    Kidney disease may affect the way this medication is processed in the body. Consult your doctor for advice.

    Liver

    Liver disease may increase the risk of side effects. Consult your doctor for advice.

References

    World Health Organization (WHO): https://www.who.int/

    Centers for Disease Control and Prevention (CDC): https://www.cdc.gov/

    Drug Manufacturer's website

Frequently Asked Questions (FAQs)
How long does it take for Padlas-L 40mg/240mg Tablet (Artemether + Lumefantrine) to work?
chevron
Is it safe to take this medication with other medicines?
chevron
What if I miss a dose?
chevron
What should I do if I experience side effects?
chevron
Is it possible to become resistant to this medication?
chevron
Last Updated On 14 May. 2025 | 08:29 PM (IST)
Report Error
Was this Product Information helpful?
Some people found this information helpful
User Feedback
Disclaimer
We, at MedCart make a diligent attempt to deliver accurate, expert-drafted and thoroughly reviewed medicine-related information to our consumers.